tirzepatide osteoarthritis Sleep Apnea and Obesity: Risks, Policy, and (Zepbound®) Semaglutide, Tirzepatide Cost-Effective in Knee

Metastasis 4 , 100025 (2022)

Check the product label

Gastrointestinal effects: the main titration bottleneck Nausea, diarrhea, constipation, and vomiting run around 40 to 44% overall, dose-dependent in how many people report them but mild-dominant in severity: severe events stay at or below about 1.7% in any category even at the top dose. In the obesity program the by-dose rates run nausea 25/29/28%, diarrhea 19/21/23%, and vomiting 8/11/13% at 5/10/15 mg. They concentrate during escalation and ease with time on a held dose

These can include hives and redness at the injection site

Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE et al